<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<rss version="2.0">
<channel>
<title>Newsroom | IDEAYA Biosciences</title>
<link>https://media.ideayabio.com/</link>
<description></description>
<item>
<title>IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors</title>
<link>https://media.ideayabio.com/2026-06-17-IDEAYA-Biosciences-Announces-Yujiro-S-Hata-Elected-Chairman-of-its-Board-of-Directors</link>
<description></description>
<pubDate>Wed, 17 Jun 2026 06:00:00 -0400</pubDate>
<guid>https://media.ideayabio.com/2026-06-17-IDEAYA-Biosciences-Announces-Yujiro-S-Hata-Elected-Chairman-of-its-Board-of-Directors</guid>
</item>
<item>
<title>IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers</title>
<link>https://media.ideayabio.com/2026-06-15-IDEAYA-Biosciences-Announces-IDE892,-a-Potential-Best-in-Class-MTA-Cooperative-PRMT5-Inhibitor,-Initiates-a-Phase-1-2-Clinical-Combination-Study-in-MTAP-Deleted-Pancreatic-and-Lung-Cancers</link>
<description></description>
<pubDate>Mon, 15 Jun 2026 06:00:00 -0400</pubDate>
<guid>https://media.ideayabio.com/2026-06-15-IDEAYA-Biosciences-Announces-IDE892,-a-Potential-Best-in-Class-MTA-Cooperative-PRMT5-Inhibitor,-Initiates-a-Phase-1-2-Clinical-Combination-Study-in-MTAP-Deleted-Pancreatic-and-Lung-Cancers</guid>
</item>
<item>
<title>IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares</title>
<link>https://media.ideayabio.com/2026-06-10-IDEAYA-Announces-Closing-of-Public-Offering-Including-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares</link>
<description></description>
<pubDate>Wed, 10 Jun 2026 16:05:00 -0400</pubDate>
<guid>https://media.ideayabio.com/2026-06-10-IDEAYA-Announces-Closing-of-Public-Offering-Including-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares</guid>
</item>
<item>
<title>IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants</title>
<link>https://media.ideayabio.com/2026-06-08-IDEAYA-Announces-Pricing-of-300-Million-Offering-of-Common-Stock-and-Pre-Funded-Warrants</link>
<description></description>
<pubDate>Mon, 08 Jun 2026 22:22:00 -0400</pubDate>
<guid>https://media.ideayabio.com/2026-06-08-IDEAYA-Announces-Pricing-of-300-Million-Offering-of-Common-Stock-and-Pre-Funded-Warrants</guid>
</item>
<item>
<title>IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants</title>
<link>https://media.ideayabio.com/2026-06-08-IDEAYA-Announces-Proposed-Public-Offering-of-Common-Stock-and-Pre-Funded-Warrants</link>
<description></description>
<pubDate>Mon, 08 Jun 2026 16:01:00 -0400</pubDate>
<guid>https://media.ideayabio.com/2026-06-08-IDEAYA-Announces-Proposed-Public-Offering-of-Common-Stock-and-Pre-Funded-Warrants</guid>
</item>
</channel>
</rss>
